# Owlet Dream Sock vs. Masimo Stork: Do Smart Socks Work?

> Both devices are now FDA-cleared, but the AAP is clear: neither prevents SIDS. Here is what each actually does, where the accuracy limits lie, and who genuinely benefits.

*Published 2026-06-25 · By Claire Bennett, CPST*

The short answer
Both the Owlet Dream Sock ($299.99) and Masimo Stork ($249–$549) are FDA-cleared OTC infant pulse oximeters that track SpO2 and pulse rate in real time. Neither device prevents SIDS — the AAP is unambiguous on that point — but both can provide clinically meaningful monitoring for families whose pediatrician has specifically recommended home pulse oximetry.

For most of the 2020s, parents searching for "baby oxygen monitor" landed in a legally murky zone. Owlet's original Smart Sock had no FDA clearance, generated passionate consumer loyalty, and received an FDA warning letter in 2021 asserting it was an uncleared medical device — resulting in a market withdrawal. By January 2024 the landscape had changed: both Owlet and Masimo had completed FDA clearance processes and launched competing over-the-counter products. The question for parents today is no longer *whether* these devices are legal but *whether they do what most buyers expect them to do.*

## How did each device get FDA clearance, and does the pathway matter?

The two clearance pathways are procedurally different but arrive at the same regulatory category.

The **Owlet Dream Sock** received **FDA De Novo clearance** in January 2024. De Novo is the pathway for novel devices — those without a legally marketed predicate — that pose low to moderate risk. De Novo classification creates a new device type and, importantly, establishes a *predicate* that future similar devices can cite in 510(k) submissions. Owlet's De Novo designates the Dream Sock as a **Class II medical device** for OTC use by healthy infants aged 1 to 18 months weighing 6 to 30 lbs.

The **Masimo Stork** used the **510(k) pathway** — predicate-based clearance — receiving an initial clearance in December 2023 for prescription use and a second 510(k) clearance on **May 6, 2024, for OTC use** with healthy infants 0–18 months weighing 6 to 30 lbs. Masimo cited its own hospital-grade [Signal Extraction Technology (SET)](https://www.masimo.com/media/masimo-receives-fda-clearance-for-stork-baby-monitoring-system) — the pulse oximetry system found in more than 10 million NICU monitors and 9 of the top 10 U.S. hospitals — as the technological foundation. The 510(k) route is common for devices with an established predicate; it does not imply a lower bar, just a different evidentiary path.

For parents, the practical takeaway is this: **both are Class II FDA-cleared medical devices** for OTC use. Neither clearance certifies that the device prevents SIDS or any specific health outcome.

Owlet also separately offers **BabySat**, a prescription-only version cleared by the FDA in June 2023, which allows clinicians to set custom alarm thresholds for SpO2 and pulse rate for infants under physician monitoring. BabySat is not available OTC and represents a meaningfully different clinical tool than the consumer Dream Sock.

## What does the accuracy data actually show — and where are the limits?

Both companies claim hospital-grade accuracy. The independent data is more nuanced.

Owlet states that the Dream Sock was clinically evaluated for SpO2 accuracy across **all Fitzpatrick Scale skin tones (Types I–VI)** under both motion and non-motion conditions, with results within ±3% of arterial blood gas measurements — the gold standard for SpO2 validation. That ±3% figure is the industry benchmark for pulse oximeter accuracy per ISO 80601-2-61.

An [independent observational study published on PubMed](https://pubmed.ncbi.nlm.nih.gov/37072015/) compared an earlier Owlet Smart Sock 3 against a hospital-grade Masimo SET pulse oximeter in 28 preterm or low-birthweight infants (1.7–2.5 kg), collecting over 21 hours of data. Key findings:

  - **Heart rate:** Strong correlation (r = 0.98, p
  Owlet Dream Sock vs. Masimo Stork: At-a-Glance Comparison (2026)

      Feature
      Owlet Dream Sock
      Masimo Stork (OTC)

      FDA clearance type
      De Novo (Class II), Jan 2024
      510(k) (Class II), May 2024

      OTC age range
      1–18 months, 6–30 lbs
      0–18 months, 6–30 lbs

      Metrics tracked
      SpO2, pulse rate, sleep trends
      SpO2, pulse rate, skin temp, room temp/humidity

      Retail price
      $299.99 (sock only)
      $249–$549 (boot; varies by bundle)

      Subscription required?
      No (Owlet360 optional at $9.99/mo)
      No (optional plan for extended features)

      Prescription tier
      BabySat (Rx only, custom thresholds)
      Initial Rx clearance Dec 2023; OTC added May 2024

      Camera bundle available?
      Yes — Dream Duo at $399
      Yes — Vitals+ bundle with 2K QHD camera

      Oximetry technology
      Proprietary pulse oximetry
      Masimo SET (hospital-grade signal extraction)

      Independent accuracy studies
      One PubMed study (Smart Sock 3, not Dream Sock)
      Extensive hospital literature; limited home-setting data

## What does the AAP actually say — and why does it matter for your buying decision?

This is the section most product reviews bury or skip. It should come first.

The **American Academy of Pediatrics 2022 Safe Sleep Policy Statement** — the current standing guidance — states explicitly: *"Home cardiorespiratory monitors should not be used to reduce the risk of SIDS."*

The AAP's reasoning is not that the devices malfunction — it is that there is no evidence they reduce SIDS incidence. SIDS (Sudden Infant Death Syndrome) remains unexplained in individual cases, and the physiological pathway(s) are not yet fully characterized. A pulse oximeter reading SpO2 within the device's measurement window cannot detect all relevant physiological events, and even catching a true low-oxygen event does not guarantee a successful intervention.

The AAP and [Nationwide Children's Hospital](https://www.nationwidechildrens.org/family-resources-education/700childrens/2025/09/wearable-baby-monitors) both document a concrete harm: **false alarms.** Oxygen saturation naturally decreases during deep sleep in healthy infants — this is normal physiology. Consumer pulse oximeters alert on thresholds calibrated for awake or lightly sleeping states. Multiple documented cases exist of parents bringing infants to emergency departments based on low Owlet readings that proved clinically normal on hospital-grade measurement. The resulting sleep deprivation and anxiety burden on parents is real and measurable.

Pediatricians writing in *Contemporary Pediatrics* acknowledge the appeal while reinforcing the same guidance: the interventions with demonstrated SIDS risk reduction are behavioral — firm, flat sleep surface; room-sharing without bed-sharing; back-to-sleep positioning; pacifier use; avoiding smoke exposure. None of these requires a $300 wearable.

**Who does benefit?** Families with medically complex infants — preterm babies, infants with congenital cardiac or pulmonary conditions, those with documented apnea — whose *pediatrician has specifically recommended home pulse oximetry.* For those families, the prescription Owlet BabySat or a physician-supervised Masimo Stork is the more clinically appropriate tool, with customized alarm thresholds set in collaboration with the care team.

Bottom line before you buy
Ask your pediatrician one direct question: does my specific baby have a documented medical indication for home pulse oximetry? If yes, ask whether BabySat or a prescription Stork with custom thresholds is covered by insurance. If no, redirect the $300 toward a FHSS video monitor, which provides eyes and ears without the false-alarm burden — and reinvest the time saved in the safe-sleep environment setup that the evidence actually supports.

*This article is general information, not medical advice. If you have concerns about your infant's breathing, oxygenation, or sleep, speak directly with your pediatrician or call your local after-hours nurse line.*

## Sources

1. [Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices](https://investors.owletcare.com/news/news-details/2024/Owlet-Transforms-Infant-Care-with-the-Launch-of-Two-FDA-Cleared-Devices--Dream-Sock-and-BabySat/default.aspx)
2. [Masimo Receives FDA Clearance for Stork Over-the-Counter (OTC) Baby Monitoring System](https://investor.masimo.com/news/news-details/2024/Masimo-Receives-FDA-Clearance-for-Stork-Over-the-Counter-OTC-Baby-Monitoring-System/default.aspx)
3. [New safe sleep recommendations can help pediatricians guide families](https://publications.aap.org/aapnews/news/20619/New-safe-sleep-recommendations-can-help)
4. [Wearable Baby Monitors: Do they Prevent SIDS?](https://www.nationwidechildrens.org/family-resources-education/700childrens/2025/09/wearable-baby-monitors)
5. [Accuracy of Wireless Pulse Oximeter on Preterm or <2.5 kg Infants](https://pubmed.ncbi.nlm.nih.gov/37072015/)
6. [Smart infant monitors: a pediatrician's guide](https://www.contemporarypediatrics.com/view/smart-infant-monitors-a-pediatrician-s-guide)
7. [Dream Sock](https://owletcare.com/products/owlet-dream-sock)
8. [Masimo Receives FDA Clearance for Stork Baby Monitoring System](https://www.masimo.com/media/masimo-receives-fda-clearance-for-stork-baby-monitoring-system)
9. [Masimo's at-home baby monitor cleared for use without prescription](https://www.medtechdive.com/news/masimo-stork-baby-monitor-fda-OTC/715310/)
10. [FDA clears Owlet Dream Sock for infant pulse oximetry](https://aasm.org/fda-clears-owlet-dream-sock-for-infant-pulse-oximetry/)

---
Source: https://natalnew.com/baby-gear/owlet-vs-masimo-smart-sock
Index: https://natalnew.com/llms.txt · Full text: https://natalnew.com/llms-full.txt